That cancer cells contain less deamidated Bcl-xL than normal cells, was a first indication that deamidated Bcl-xL harbors impaired anti-apoptotic functions; [20, 22, 23] in vitro studies further showed that Bcl-xL deamidation inhibited binding to BH3-containing partners. Here, BCL2L1 is linked to cancer.